Loading...
XTAI1789
Market cap534mUSD
Dec 24, Last price  
22.05TWD
1D
0.23%
1Q
-13.70%
Jan 2017
-40.66%
IPO
-53.69%
Name

ScinoPharm Taiwan Ltd

Chart & Performance

D1W1MN
XTAI:1789 chart
P/E
60.74
P/S
5.47
EPS
0.36
Div Yield, %
1.63%
Shrs. gr., 5y
-0.02%
Rev. gr., 5y
-2.00%
Revenues
3.19b
-2.39%
3,813,072,0003,891,113,0003,953,578,0004,572,509,0005,088,245,0004,097,844,0003,955,207,0004,030,921,0003,516,481,0003,524,263,0002,892,783,0003,082,928,0002,762,335,0003,264,045,0003,186,083,000
Net income
287m
-18.73%
1,041,033,0001,040,003,000959,355,0001,170,469,0001,273,404,000484,143,000634,965,000658,693,000422,367,000442,978,000216,656,000282,067,000243,471,000353,216,000287,056,000
CFO
231m
-70.13%
1,297,804,0001,564,380,0001,294,307,0001,021,055,000939,473,000888,295,0001,044,530,0001,665,024,000971,714,0001,231,594,000788,945,000946,312,000509,823,000773,791,000231,126,000
Dividend
Jul 04, 20240.3 TWD/sh
Earnings
Feb 25, 2025

Profile

ScinoPharm Taiwan, Ltd., together with its subsidiaries, researches and develops, produces, and sells cGMP active pharmaceutical ingredients (API) to pharmaceutical companies in Taiwan, the United States, Europe, India, rest of Asia, and internationally. The company offers custom synthesis services for biochemistry molecules, such as peptides and nucleic acids; generic API manufacturing services; and outsourcing services. It also provides CRAM services, such as chemistry skill, analytical and regulatory, chemical process development, clinical drug substance, and consulting services for the development and manufacturing of clinical, small-scale, and commercial-stage APIs and intermediates. In addition, the company develops peptide synthesis technologies. Further, it develops and manufactures western medicines and other chemical materials, albumin medicines, oligonucleotide medicines, injections, and new small molecule drugs, as well as provides biological technology services and technical services. It has a strategic alliance with Baxter International Inc. to develop, manufacture, and commercialize of antiemetic drug in chemotherapy for cancer. ScinoPharm Taiwan, Ltd. was incorporated in 1997 and is headquartered in Tainan City, Taiwan.
URL
https://www.scinopharm.com.tw/
IPO date
Oct 29, 2010
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
3,186,083
-2.39%
3,264,045
18.16%
2,762,335
-10.40%
Cost of revenue
2,871,659
2,858,412
2,473,592
Unusual Expense (Income)
NOPBT
314,424
405,633
288,743
NOPBT Margin
9.87%
12.43%
10.45%
Operating Taxes
61,784
84,744
58,815
Tax Rate
19.65%
20.89%
20.37%
NOPAT
252,640
320,889
229,928
Net income
287,056
-18.73%
353,216
45.08%
243,471
-13.68%
Dividends
(284,666)
(379,555)
(395,370)
Dividend yield
1.36%
1.88%
2.02%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
50,872
96,727
17,337
Long-term debt
1,158,018
1,180,255
1,096,697
Deferred revenue
79,546
Other long-term liabilities
55,811
76,848
3,648
Net debt
(2,833,547)
(3,161,283)
(3,181,953)
Cash flow
Cash from operating activities
231,126
773,791
509,823
CAPEX
(268,429)
(250,044)
(321,320)
Cash from investing activities
(233,290)
(253,618)
(69,981)
Cash from financing activities
(340,977)
(314,827)
(412,774)
FCF
579,273
(218,915)
58,744
Balance
Cash
3,949,828
4,345,841
4,131,632
Long term investments
92,609
92,424
164,355
Excess cash
3,883,133
4,275,063
4,157,870
Stockholders' equity
9,099,094
9,155,364
9,216,365
Invested Capital
7,158,211
6,830,110
6,922,815
ROIC
3.61%
4.67%
3.33%
ROCE
2.85%
3.65%
2.61%
EV
Common stock shares outstanding
792,328
792,681
792,284
Price
26.40
3.73%
25.45
3.25%
24.65
-14.56%
Market cap
20,917,459
3.69%
20,173,731
3.30%
19,529,801
-14.55%
EV
18,083,912
17,012,448
16,347,848
EBITDA
775,591
845,098
670,275
EV/EBITDA
23.32
20.13
24.39
Interest
9,147
7,913
6,548
Interest/NOPBT
2.91%
1.95%
2.27%